Agios Pharmaceuticals (NASDAQ:AGIO) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report published on Wednesday morning,Benzinga reports.

A number of other equities analysts also recently issued reports on AGIO. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Down 4.7 %

Shares of Agios Pharmaceuticals stock traded down $1.83 on Wednesday, reaching $37.19. The stock had a trading volume of 164,649 shares, compared to its average volume of 719,730. Agios Pharmaceuticals has a 1 year low of $20.96 and a 1 year high of $62.58. The company has a 50 day moving average price of $50.06 and a 200 day moving average price of $46.78. The stock has a market capitalization of $2.12 billion, a P/E ratio of 3.27 and a beta of 0.80.

Insider Activity

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently made changes to their positions in AGIO. Farallon Capital Management LLC grew its holdings in Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after acquiring an additional 63,900 shares during the period. State Street Corp increased its holdings in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after purchasing an additional 216,484 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Agios Pharmaceuticals during the third quarter worth $97,199,000. Geode Capital Management LLC grew its position in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after buying an additional 6,101 shares during the period. Finally, Marshall Wace LLP increased its holdings in Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.